Roche
-
Fenebrutinib: First New Treatment in Over a Decade to Combat Progressive MS Disability
Roche’s investigational drug, fenebrutinib, shows promise in slowing disability progression for primary progressive multiple sclerosis (PPMS). As a BTK inhibitor, it targets inflammation in the central nervous system. This potential breakthrough offers hope for PPMS patients, who have had limited treatment options. The success of fenebrutinib could also validate BTK inhibitors for other neurological conditions, driving further research and investment.
-
Giredestrant Improves Progression-Free Survival in ER-Positive Advanced Breast Cancer: Roche’s Phase III evERA Trial
Roche’s Phase III evERA trial showed promising results for giredestrant plus everolimus in ER-positive, HER2-negative advanced breast cancer after CDK4/6 inhibitor therapy. The combination significantly improved progression-free survival (PFS) compared to standard endocrine therapy plus everolimus. The PFS risk reduction was 44% in ITT and 62% in ESR1-mutated patients. While overall survival data is still maturing, a positive trend was observed. Giredestrant + everolimus could become a new standard of care.
